Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 5/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 11/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 4/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | CPA2 | P48052 | 1/20 | 0.39 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6569052 | 0.92 | BACE1 (0.46) | CASP3CASP1CASP7CASP9BACE1 | |
| SCHEMBL3178459 | 0.89 | CASP3 (0.41) | CASP3CASP1CASP7CASP9BACE1 | |
| SCHEMBL77937 | 0.85 | OPRD1 (0.51) | CASP3CASP1CASP7BACE1BACE2 | |
| SCHEMBL6570634 | 0.80 | OPRD1 (0.57) | CASP1BACE1BACE2 | |
| SCHEMBL2168561 | 0.77 | CASP3 (0.41) | CASP3CASP1CASP7CASP9BACE1 | |
| SCHEMBL7163106 | 0.76 | BACE1 (0.50) | CASP3CASP1CASP7CASP9BACE1 | |
| SCHEMBL1552674 | 0.76 | KDM4E (0.53) | CASP3POLBSMN1; SMN2 | |
| SCHEMBL29445883 | 0.76 | KDM4E (0.53) | CASP3POLBSMN1; SMN2 | |
| SCHEMBL3363734 | 0.76 | BACE1 (0.35) | CASP3BACE1BACE2CASP8CASP6 | |
| SCHEMBL7165565 | 0.74 | CASP3 (0.55) | CASP3CASP1CASP7CASP9BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956260-B1 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-05-01 | — | — | US | disclosed |
| US-9352010-B2 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2016-01-14 | — | — | US | disclosed |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2015-12-03 | — | — | US | disclosed |
| US-8362043-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8129381-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2412707-A2 | 3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1833794-B1 | 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| US-5968927-A | AZEPINO-INDOLE COMPOUNDS; TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, PREVENTION OF ISCHEMIC INJURY | IDUN PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0929311-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | Idun Pharmaceuticals, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0920444-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5877197-A | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 1999-03-02 | — | — | US | disclosed |
| US-5869519-A | USE OF SUCH COMPOSITIONS IN THE TREATMENT OF PATIENTS SUFFERING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, FOR THE PREVENTION OF ISCHEMIC INJURY, AND FOR THE PRESERVATION OF ORGANS THAT ARE TO UNDERGO A TRANSPLANTATION | IDUN PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0874850-A1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | Idun Pharmaceuticals, Inc. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998010778-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011129-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011109-A1 | NOVEL TRICYCLIC COMPOUNDS FOR THE INHIBITION OF THE ICE/CED-3 PROTEASE FAMILY OF ENZYMES | IDUN PHARMACEUTICALS, INCORPORATED (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP3 18/4885CASP1 2/4885CASP7 17/4885 |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | CASP3 2/4885CASP1 1/4885CASP7 6/4885 |
| US-20160008420-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | CASP3 18/4885CASP1 2/4885CASP7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.